The treatment options for attentiondeficit/hyperactivity disorder (ADHD) continue to expand. In the past 3 years, the Food and Drug Administration (FDA) has approved several new products. This issue of Pediatric Pharmacotherapy will provide a review of two new treatment options for children with ADHD: a transdermal methylphenidate delivery system, and lisdexamfetamine, an inactive dexamphetamine pro-drug.
Pediatr Pharm. 2008;14(3) © 2008 Children's Medical Center, University of Virginia
Cite this: New Treatment Options for Attention-Deficit/Hyperactivity Disorder (ADHD): Part I. Transdermal Methylphenidate and Lisdexamfetamine - Medscape - Mar 01, 2008.